April 16th, 2024
Paper published: Clinical trial about Boron Neutron Capture Therapy for recurrent breast cancer
Our company provides Steboronine® for the investigator-initiated specified clin……
Press Release
The international science journal “Nature” published in its special edition “Ra……
March 14th, 2024
Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma
Our company provides the boron drug for BNCT (Boron Neutron Capture Therapy), w……
March 4th, 2024
Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer
The results regarding safety and effectiveness of our product Borofalan(10B), u……
January 11th, 2024
Investigator-initiated Phase I BNCT clinical trial for newly diagnosed glioblastoma
We would like to announce that Phase I clinical trial for newly diagnosed gliob……
December 13th, 2023
Stella Pharma, Mitsubishi Chemical Group, and the University of Tokyo conclude Joint Research Agreement—Accelerating practical application of polyvinyl alcohol (PVA) for boron neutron capture therapy (BNCT)—
Stella Pharma Corporation , Mitsubishi Chemical Corporation of the Mitsubishi C……
June 24th, 2022
Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China
Sumitomo Heavy Industries, Ltd. and STELLA PHARMA CORPORATION have respectively……
May 19th, 2020
STELLA PHARMA will launch Steboronine®, the World’s First BNCT Drug, on May 20, 2020
STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki……
March 25th, 2020
STELLA PHARMA Receives Marketing and Manufacturing Approval in Japan for “Steboronine® Intravenous Drip Bag 9000mg/300mL
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City, President: Tomoyuk……
January 23rd, 2020
How to keep boron inside cells during radiotherapy: a simple novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p‐boronophenylalan……
November 7th, 2019
“Commencement of Clinical Trial of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma and Angiosarcoma” issued
Cancer Intelligence Care Systems, Inc. (“CICS;” President: Tetsuya Furukawa; he……
October 15th, 2019
STELLA PHARMA CORPORATION has recently filed for approval to manufacture and sell a boron agent for BNCT
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City; President: Tomoyuk……
